Clobetasol


Concise Prescribing Info
Indications/Uses
Corticosteroid-responsive dermatoses.
Dosage/Direction for Use
Adult : Topical As 0.05% oint/cream/lotion/gel/scalp soln: Apply thinly onto the affected area once daily or bid, reduced if necessary. Max dose: 50 g wkly. Max duration of therapy: 4 wk. As 0.05% shampoo: Apply directly on dry scalp once daily. Max duration of therapy: 4 wk. As 0.05% foam: Apply to affected area bid. Max dose: 50g wkly. Max duration of therapy: 2 wk.
Dosage Details
Topical/Cutaneous
Corticosteroid-responsive dermatoses
Adult: As 0.05% oint/cream/lotion/gel/scalp soln: Apply thinly and rub gently onto the affected area once daily or bid, reduced if necessary. Max dose: 50 g wkly. Max duration of therapy: 4 wk.
Child: >1 yr Same as adult dose. Max duration of therapy: 5 days.

Topical/Cutaneous
Corticosteroid-responsive dermatoses
Adult: As 0.05% foam: Apply to affected area bid. Max: 50g wkly. Max duration of therapy: 2 wk.

Topical/Cutaneous
Corticosteroid-responsive dermatoses
Adult: As 0.05% shampoo: Apply directly on dry scalp once daily, leave for 15 min. Do not cover w/ shower cap. Max duration of therapy: 4 wk.
Contraindications
Untreated bacterial, fungal or viral skin lesions, rosacea, perioral dermatitis, acne, and plaque psoriasis. Childn <1 yr (oint/cream/lotion/gel/scalp soln); <2 yr (shampoo).
Special Precautions
Childn. Pregnancy and lactation.
Adverse Reactions
Significant: Hypothalamic-pituitary-adrenal (HPA) axis suppression or hypercorticism (i.e. Cushing’s syndrome, hyperglycaemia, glycosuria), contact dermatitis, skin irritation.
Nervous: Numbness of fingers.
CV: Intracranial HTN e.g. bulging fontanelles, headaches, bilateral papilledema.
Dermatologic: Burning and stinging sensation, tingling, cracking, irritation, itching, dryness, hypopigmentation, maceration, erythema, folliculitis, perioral dermatitis, skin atrophy, acneiform, hypertrichosis, tenderness, telangiectasia, striae, miliaria, alopecia, pustules and tightening of the scalp.
Patient Counseling Information
Avoid use w/ occlusive dressing. Avoid contact w/ face (i.e. eyes, nose, mouth), axillae, or groin. Clobetasol foam is flammable, do not smoke during or immediately after application.
MonitoringParameters
Monitor for hypothalamic-pituitary-adrenal (HPA) axis suppression through ACTH stimulation test, morning plasma cortisol test, and urinary free cortisol test.
Drug Interactions
Increased systemic exposure w/ CYP3A4 enzyme inhibitors (e.g. itraconazole, ritonavir). May diminish the antineoplstic effect of aldesleukin. May potentiate the hyperglycaemic effect of ceritinib. May diminish the therapeutic effect of corticorelin and hyaluronidase. May enhance the adverse/toxic effects of deferasinox.
Action
Description: Clobetasol is a very potent topical glucocorticoid w/ anti-inflammatory, antipruritic, and vasoconstrictive effects. It promotes induction of phospholipase A2 inhibitory proteins (lipocortins), subsequently inhibiting the release of arachidonic acid, thereby depressing the formation, release, and activity of endogenous chemical mediators of inflammation (e.g. histamine, leukotrienes, prostaglandins).
Pharmacokinetics:
Absorption: Variable absorption depending on dose, integrity of epidermis, vehicle used, and use of occlusive dressing.
Distribution: Minimal distribution to the dermis.
Metabolism: Metabolised in the liver.
Excretion: Via urine and faeces.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 20-25°C. Do not refrigerate.
ATC Classification
D07AD01 - clobetasol ; Belongs to the class of very potent (group IV) corticosteroids. Used in the treatment of dermatological diseases.
Disclaimer: This information is independently developed by MIMS based on Clobetasol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Clonate
  • Dhabesol
  • Univate
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in